U.S. FDA Approves Japan Tobacco's Single-Dose Anti-HIV Drug
This article was originally published in PharmAsia News
Japan Tobacco's JTK-303 single-dose anti-HIV drug won approval by the U.S. FDA as applied by Gilead Sciences, the U.S. company with global rights to develop and market the drug except in Japan.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.